Sponsor study identifier
observational
100
1 country
1
Study Start
March 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2009
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2009
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
After transplantation, if insufficient immunosuppression is achieved, rejection and graft loss follows. If to much immunosuppression is given, the patient suffers risk for infections and malignancies. Despite careful dosing and monitoring of drug levels, the biological effects of the immunosuppression given is difficult to predict and varies significantly. As a result, the degree of immunosuppression (or immunosuppressive status) remains unknown and clinical problems related to under- or over-immunosuppression are common. Thus, a method to determine the degree of immunosuppression would be of great and direct clinical importance and the results would be improved. T cells are the principal cells of the immunesystem causing rejection. Furthermore, all immunosuppressive regimes targets T cells. Thus, T cell reactivity could reflect the biological effects of the immunosuppression and the immunosuppressive status. In addition, T cells are of crucial importance in the immunedefence against viral diseases. Therefore, data on virus specific T cell reactivity could aid in diagnosis, monitoring and treatment of viral disease. The proposed study aim to develop a clinically useful method to monitor cellular immunity and the degree of immunosuppression after transplantation by determinations of the specific T cell reactivity to several clinically relevant viruses.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2009
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2007
Date type not reportedThis date has not been verified as actual or estimated.
May 21, 2008
Actual (reported)May 23, 2008
Actual (reported)March 2009
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 2009
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
T cell reactivity to viral antigens
Pre-transplantation and 2 weeks, 1, 3, 6 and 12 months after transplantation
All patients undergoing kidney or liver transplantation at the Karolinska University Hospital
Lars Wennberg
Stockholm, 14186, Sweden
Serum, whole blood
Lars Wennberg, MD, PhD
Karolinska University Hospital
Gunnar Tyden, MD, PhD
Karolinska University Hospital
First Submitted
May 21, 2008
First Posted
May 23, 2008
Study Start
March 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2009
Estimated (date passed)Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2009
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
February 5, 2009
Record last verified: 2009-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: